BML Capital Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 7, 2026), BML Capital Management, LLC reported 15 stock positions worth $175.1 million. Its top holding was Aclaris Therapeutics (ACRS) at 36.2% of the portfolio, followed by Atea Pharmaceuticals (AVIR, 18.5%) and Engene Therapeutics (ENGN, 6.6%). Compared with Q1 2026, it opened 1 new position, sold out of 1, added to 5 and reduced 3. The biggest buy was a new position in Engene Therapeutics (ENGN) and the biggest sale Atea Pharmaceuticals (AVIR, shares −2%).
- Most Recent 13F
- Q2 2026
- Location
- ZIONSVILLE, IN
- CIK
- 0001616824
- Portfolio Value
- $175.1M (Q2 2026)
- SEC Filing
- 0001754960-26-000696 ↗ filed Aug 7, 2026
Holdings Value
Holdings 15 stocks · $175.1M
| ACRS Aclaris Therapeutics Inc. | 36.18% | 11,975,000 | $63.3M | Reduce -16.0% |
| AVIR Atea Pharmaceuticals Inc. | 18.46% | 6,952,330 | $32.3M | Reduce -1.5% |
| ENGN Engene Therapeutics Inc. | 6.59% | 6,669,908 | $11.5M | New |
| KHC The Kraft Heinz Co. | 6.27% | 465,000 | $11.0M | Add +272.0% |
| OM Outset Medical Inc. | 6.22% | 2,519,701 | $10.9M | Add +32.5% |
| KMX Carmax Inc. | 5.21% | 172,500 | $9.1M | Add +11.3% |
| TLYS Tilly's Inc. Class A SHRS | 5.16% | 2,150,000 | $9.0M | No change |
| PMVP PMV Pharmaceuticals Inc. | 4.08% | 5,330,000 | $7.1M | Add +0.2% |
| TIL Instil Bio Inc. | 2.84% | 645,600 | $5.0M | No change |
| TGT Target Corp. | 2.80% | 37,500 | $4.9M | No change |
| ORMP Oramed Pharmaceuticals Inc. | 2.38% | 866,269 | $4.2M | Reduce -72.7% |
| JANX Janux Therapeutics Inc. | 1.36% | 154,961 | $2.4M | No change |
| PLRX Pliant Therapeutics Inc. | 1.01% | 1,546,137 | $1.8M | No change |
| CNTB Connect Biopharma Holdings L | 0.78% | 573,287 | $1.4M | Add +40.2% |
| IMA Imagenebio Inc. | 0.68% | 200,730 | $1.2M | No change |
Options reported separately and not counted above: WMT puts ($386K), CORZ puts ($298K), TSLA puts ($270K).
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
Options Activity Q1 2026 → Q2 2026
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $175.1M | ACRS, AVIR, ENGN, KHC, OM |
| Q1 2026 | 15 | $155.4M | ACRS, AVIR, ORMP, TLYS, OM |
| Q4 2025 | 13 | $113.0M | ACRS, AVIR, ORMP, TIL, PMVP |
| Q3 2025 | 19 | $108.7M | ACRS, AVIR, ADVM, TIL, ORMP |
| Q2 2025 | 23 | $130.5M | AVIR, THRD, ACRS, TIL, EPIX |
| Q1 2025 | 27 | $123.6M | AVIR, ACRS, THRD, ADVM, ANTX |
| Q4 2024 | 25 | $161.0M | ACRS, SGOV, AVIR, ADVM, ANTX |
| Q3 2024 | 29 | $169.9M | SGOV, TIL, AVIR, ACRS, BIL |
| Q2 2024 | 27 | $136.5M | SGOV, AVIR, BIL, ACRS, ADVM |
| Q1 2024Amended | 30 | $149.4M | SGOV, AVIR, BIL, ADVM, ACRS |